RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial-Reference-Cited by-同舟云学术

RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

Published:2021-04 Issue: Volume:34 Page:100843
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Lopardo Gustavo,Belloso Waldo H.,Nannini Esteban,Colonna Mariana,Sanguineti Santiago,Zylberman Vanesa,Muñoz Luciana,Dobarro Martín^ORCID,Lebersztein Gabriel,Farina Javier,Vidiella Gabriela,Bertetti Anselmo,Crudo Favio,Alzogaray Maria Fernanda,Barcelona Laura,Teijeiro Ricardo,Lambert Sandra,Scublinsky Darío,Iacono Marisa,Stanek Vanina^ORCID,Solari Rubén,Cruz Pablo,Casas Marcelo Martín,Abusamra Lorena,Luciardi Héctor Lucas,Cremona Alberto,Caruso Diego,de Miguel Bernardo,Lloret Santiago Perez,Millán Susana,Kilstein Yael,Pereiro Ana,Sued Omar,Cahn Pedro,Spatz Linus,Goldbaum Fernando^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. https://www.worldometers.info/coronavirus/. COVID-19 coronavirus pandemic. (accessed January 15th, 2021).

2. Association between administration of systemic corticosteroids and mortality among critically III patients with COVID-19;Sterne;JAMA,2020

3. Dexamethasone in Hospitalized Patients with Covid-19;N Engl J Med,2021

4. Remdesivir for the treatment of COVID-19 — final report;Beigel;N Engl J Med,2020

5. Remdesivir for 5 or 10 days in patients with severe COVID-19;Goldman;N Engl J Med,2020

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome;2024-08-22

2. Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review);Molecular Medicine Reports;2024-06-26

3. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19;Frontiers in Immunology;2024-04-17

4. A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)₂ fragments in healthy volunteers;British Journal of Clinical Pharmacology;2024-01-30

5. Potential role of hyperimmune milk as a source of passive immunotherapy against COVID-19: A review;International Dairy Journal;2023-12